Stock Events

Stock Events

Sigyn Therapeutics 

$0.03
4
+$0.01+48.81% Thursday 17:09

Statistics

Day High
0.03
Day Low
0.02
52W High
5
52W Low
0.01
Volume
26,200
Avg. Volume
92,554
Mkt Cap
40,125
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Nov 4
$8.25
Jul 4
$47.15
Nov 3
$6.8
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-6.68MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SIGY. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Cytodyn
CYDY
Mkt Cap302.34M
CytoDyn Inc. focuses on innovative treatments for autoimmune diseases and HIV, which overlaps with Sigyn Therapeutics' focus on therapeutic technologies for sepsis and other inflammatory conditions.
Sorrento Therapeutics
SRNE
Mkt Cap826,922
Sorrento Therapeutics, Inc. works on therapies for cancer, inflammation, and autoimmune diseases, competing in the inflammatory and immune-modulating treatment space.
XBiotech
XBIT
Mkt Cap71.65M
XBiotech Inc. specializes in the discovery and development of monoclonal antibodies for treating various inflammatory conditions, directly competing with Sigyn's approach to treating systemic inflammation.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation has a broad portfolio in oncology and inflammation, potentially competing in the development of treatments for conditions targeted by Sigyn Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. offers treatments for inflammatory and immune diseases, directly competing with Sigyn's focus on inflammatory conditions.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. has a diverse portfolio including treatments for viral diseases, inflammatory, and oncological conditions, overlapping with Sigyn's therapeutic areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. has a broad focus on biologics in various therapeutic areas, including inflammation and oncology, which could compete with Sigyn's technology in treating systemic inflammation.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. focuses on immunology and oncology, with a strong pipeline in anti-inflammatory treatments, potentially competing with Sigyn's therapeutic approach.

About

Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
Show more...
CEO
Mr. James A. Joyce Ph.D.
Employees
4
Country
US
ISIN
US82674U2050

Listings

OTC Link
US
SIGY

0 Comments

Share your thoughts

FAQ

What is Sigyn Therapeutics stock price today?▼
The current price of SIGY is $0.03 USD — it has increased by +48.81% in the past 24 hours. Watch Sigyn Therapeutics stock price performance more closely on the chart.
What is Sigyn Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sigyn Therapeutics stocks are traded under the ticker SIGY.
What is Sigyn Therapeutics market cap?▼
Today Sigyn Therapeutics has the market capitalization of 40,125
When is the next Sigyn Therapeutics earnings date?▼
Sigyn Therapeutics is going to release the next earnings report on May 19, 2026.
What is Sigyn Therapeutics revenue for the last year?▼
Sigyn Therapeutics revenue for the last year amounts to 0 USD.
What is Sigyn Therapeutics net income for the last year?▼
SIGY net income for the last year is -6.68M USD.
Does Sigyn Therapeutics pay dividends?▼
Yes, SIGY dividends are paid en. The last dividend per share was 8.25 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Sigyn Therapeutics have?▼
As of April 05, 2026, the company has 4 employees.
In which sector is Sigyn Therapeutics located?▼
Sigyn Therapeutics operates in the Health Care sector.
When did Sigyn Therapeutics complete a stock split?▼
The last stock split for Sigyn Therapeutics was on January 31, 2024 with a ratio of 1:40.
Where is Sigyn Therapeutics headquartered?▼
Sigyn Therapeutics is headquartered in San Diego, US.